Small molecule · Inhibitor of extracellular signal-regulated kinase 1 (MAPK3) and extracellular signal-regulated kinase 2 (MAPK1) · developed by Erasca
ERAS-007 is an orally bioavailable small molecule that binds and inhibits the kinase activities of ERK1 and ERK2, preventing phosphorylation of their substrates and blocking MAPK/ERK-mediated signaling. It is being studied in advanced or metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04866134 | Phase 1/2 | Advanced or Metastatic Solid Tumors | Completed | ERAS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the ERAS page.
See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ERAS catalysts and pipeline →